Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Munich – page 84

1 191 clinical trials in Munich, Germany across 8 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Munich at a glance
1 191
clinical trials
  • Research sites8
Type of trial
Recruitment status
Quick filters

1 191 trials in Munich

Open in trial search

Study Comparing Datopotamab Deruxtecan to Chemotherapy in Patients with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Asthma

Not recruiting

Study Comparing Depemokimab, Mepolizumab, and Benralizumab for Adults and Adolescents with Severe Eosinophilic Asthma

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on the Tolerability and Efficacy of Asciminib vs. Nilotinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Novartis Pharma AG
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Nusinersen
  • Sponsor:Biogen Idec Research Limited

Fabry's disease

Not recruiting

Study of venglustat tablets to reduce neuropathic and abdominal pain in patients aged 16 and older with Fabry disease who are untreated or haven't received treatment for 6 months

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Venglustat
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on Afatinib and Osimertinib for Patients with EGFR-Mutated, T790M Negative Non-Squamous Non-Small Cell Lung Cancer in First-Line Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Afatinib
  • Sponsor:Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR

Study on the Safety of Osimertinib with Radiation for Patients with Stage IV EGFR-Mutation Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Osimertinib
  • Sponsor:AIO-Studien gGmbH

Study on Tezepelumab for Symptom Relief in Patients Aged 12-80 with Eosinophilic Esophagitis

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:AstraZeneca AB

Study comparing 177Lu-edotreotide versus everolimus in patients with inoperable progressive neuroendocrine tumors of gastroenteric or pancreatic origin

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:ITM Solucin GmbH

Cystic fibrosis

Not recruiting

Study on Long-term Safety of VX-121, Tezacaftor, and Deutivacaftor in Patients with Cystic Fibrosis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deutivacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Colitis ulcerative

Not recruiting

Study of Tofacitinib for Children with Moderate to Severe Ulcerative Colitis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Tofacitinib
  • Sponsor:Pfizer Inc.

Study of Cemiplimab Compared to Placebo After Surgery and Radiation for Patients with High-Risk Skin Squamous Cell Carcinoma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Munich

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on various cancer types, including metastatic prostate cancer, colorectal cancer, and bladder cancer. Novel therapeutic approaches combining immunotherapy with established treatments are being investigated.

  • Prostate Cancer Treatment Innovations
  • Colorectal Cancer Therapies
  • Early-Stage Bladder Cancer Management

Research aims to improve survival rates and treatment effectiveness through targeted therapies and immunological approaches.

02 Cardiovascular and Hematological Studies

Important research in heart disease and blood conditions, including studies on TTR amyloidosis and prevention of thrombotic events. Novel medications are being tested to improve patient outcomes.

  • Cardiac Amyloidosis Treatment
  • Thrombosis Prevention
  • Cardiovascular Disease Management

Focus on developing innovative treatments for complex cardiovascular conditions and preventing blood clots.

03 Neurology and Mental Health

Advanced research into neurological conditions, particularly focusing on Alzheimer's disease and autoimmune dementia. Studies aim to develop new therapeutic approaches and improve diagnostic tools.

  • Early-Stage Alzheimer's Treatment
  • Autoimmune Dementia Therapy
  • Cognitive Function Studies

Innovative approaches to treating and managing neurodegenerative conditions.

04 Immunology and Infectious Diseases

Critical research in HIV prevention and immune system modulation, including studies on transplant medicine and vaccine development for yellow fever.

  • HIV Pre-Exposure Prophylaxis
  • Transplant Immunology
  • Vaccine Development

Focus on preventing infectious diseases and improving transplant outcomes through immunological interventions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.